594 related articles for article (PubMed ID: 22104539)
1. Differences in biomarkers in patients with heart failure with a reduced vs a preserved left ventricular ejection fraction.
de Denus S; Lavoie J; Ducharme A; O'Meara E; Racine N; Sirois MG; Neagoe PE; Zhu L; Rouleau JL; White M
Can J Cardiol; 2012; 28(1):62-8. PubMed ID: 22104539
[TBL] [Abstract][Full Text] [Related]
2. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction.
Linssen GC; Rienstra M; Jaarsma T; Voors AA; van Gelder IC; Hillege HL; van Veldhuisen DJ
Eur J Heart Fail; 2011 Oct; 13(10):1111-20. PubMed ID: 21642293
[TBL] [Abstract][Full Text] [Related]
3. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
[TBL] [Abstract][Full Text] [Related]
4. Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide.
Abulhul E; McDonald K; Martos R; Phelan D; Spiers JP; Hennessy M; Baugh J; Watson C; O'Loughlin C; Ledwidge M
Clin Ther; 2012 Jan; 34(1):91-100. PubMed ID: 22154198
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory pathways in patients with heart failure and preserved ejection fraction.
Niethammer M; Sieber M; von Haehling S; Anker SD; Munzel T; Horstick G; Genth-Zotz S
Int J Cardiol; 2008 Sep; 129(1):111-7. PubMed ID: 17658631
[TBL] [Abstract][Full Text] [Related]
6. Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure.
Koç M; Bozkurt A; Yildiray-Sahin D; Unal I; Acartürk E
Cardiol J; 2009; 16(1):43-9. PubMed ID: 19130415
[TBL] [Abstract][Full Text] [Related]
7. Relationship of circulating matrix biomarkers to myocardial matrix metabolism in advanced heart failure.
Kaye DM; Khammy O; Mariani J; Maeder MT
Eur J Heart Fail; 2013 Mar; 15(3):292-8. PubMed ID: 23143794
[TBL] [Abstract][Full Text] [Related]
8. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.
Lopez-Andrès N; Rossignol P; Iraqi W; Fay R; Nuée J; Ghio S; Cleland JG; Zannad F; Lacolley P
Eur J Heart Fail; 2012 Jan; 14(1):74-81. PubMed ID: 22089058
[TBL] [Abstract][Full Text] [Related]
9. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?
Collier P; Watson CJ; Voon V; Phelan D; Jan A; Mak G; Martos R; Baugh JA; Ledwidge MT; McDonald KM
Eur J Heart Fail; 2011 Oct; 13(10):1087-95. PubMed ID: 21719449
[TBL] [Abstract][Full Text] [Related]
10. Serum markers of deranged myocardial collagen turnover: their relation to malignant ventricular arrhythmias in cardioverter-defibrillator recipients with heart failure.
Flevari P; Theodorakis G; Leftheriotis D; Kroupis C; Kolokathis F; Dima K; Anastasiou-Nana M; Kremastinos D
Am Heart J; 2012 Oct; 164(4):530-7. PubMed ID: 23067911
[TBL] [Abstract][Full Text] [Related]
11. Type 2 Diabetes Mellitus and Chronic Heart Failure with Midrange and Preserved Ejection Fraction: A Focus on Serum Biomarkers of Fibrosis.
Lebedev DA; Lyasnikova EA; Vasilyeva EY; Babenko AY; Shlyakhto EV
J Diabetes Res; 2020; 2020():6976153. PubMed ID: 33224989
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.
Grewal J; McKelvie RS; Persson H; Tait P; Carlsson J; Swedberg K; Ostergren J; Lonn E
Am J Cardiol; 2008 Sep; 102(6):733-7. PubMed ID: 18773998
[TBL] [Abstract][Full Text] [Related]
13. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients.
Lin YH; Lin LY; Wu YW; Chien KL; Lee CM; Hsu RB; Chao CL; Wang SS; Hsein YC; Liao LC; Ho YL; Chen MF
Clin Chim Acta; 2009 Nov; 409(1-2):96-9. PubMed ID: 19747906
[TBL] [Abstract][Full Text] [Related]
14. Plasma amino-terminal pro-brain natriuretic peptide: a novel approach to the diagnosis of cardiac dysfunction.
Campbell DJ; Mitchelhill KI; Schlicht SM; Booth RJ
J Card Fail; 2000 Jun; 6(2):130-9. PubMed ID: 10908087
[TBL] [Abstract][Full Text] [Related]
15. Role of the plasma brain natriuretic peptide in differentiating patients with congestive heart failure from other diseases.
Sirithunyanont C; Leowattana W; Sukumalchantra Y; Chaisupamonkollarp S; Watanawaroon S; Chivatanaporn B; Bhuripanyo K; Mahanonda N
J Med Assoc Thai; 2003 May; 86 Suppl 1():S87-95. PubMed ID: 12866774
[TBL] [Abstract][Full Text] [Related]
16. Comparative value of BNP and NT-proBNP in diagnosis of heart failure.
Fonseca C; Sarmento PM; Minez A; Gonçalves E; Covas R; Dias AR; Pina MJ; Ceia F
Rev Port Cardiol; 2004; 23(7-8):979-91. PubMed ID: 15478324
[TBL] [Abstract][Full Text] [Related]
17. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
[TBL] [Abstract][Full Text] [Related]
18. Comparison of predictive value of NT-proBNP, sST2 and MMPs in heart failure patients with different ejection fractions.
Pan W; Yang D; Yu P; Yu H
BMC Cardiovasc Disord; 2020 Apr; 20(1):208. PubMed ID: 32354356
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for left ventricular dysfunction in patients with chronic kidney disease stage 5 on haemodialysis.
David S; Kümpers P; Seidler V; Biertz F; Haller H; Fliser D
Nephrol Dial Transplant; 2008 Apr; 23(4):1370-7. PubMed ID: 18089624
[TBL] [Abstract][Full Text] [Related]
20. [Changes in NT-proBNP levels in patients with atrial fibrillation related to heart failure].
Pokorná V; Jurkovicová O; Kaluzay J; Stecová A; Pont'uch P
Vnitr Lek; 2010 Aug; 56(8):788-94. PubMed ID: 20845610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
